SHIPPEO
13.6.2022 10:02:09 CEST | Business Wire | Press release
Shippeo , a leading provider of global and multimodal shipment visibility, has partnered with Everysens , a leader in rail and intermodal transport management systems, to enhance their multimodal transport visibility offering. Everysens will provide Shippeo with the most reliable rail ETA available on the market, based on real-time data from satellite tracking and rail operators.
The two-way partnership allows Everysens to also benefit from Shippeo’s large network of road and ocean carriers, providing high quality shipment tracking data to rail and intermodal shippers and their customers. By sharing container events for ocean shipments, as well as highly accurate and reliable road freight ETAs , Everysens can better anticipate impacts on rail logistics .
In turn, Shippeo receives a stream of rail events from Everysens , including ETAs, GPS positions and loading statuses. Everysens provides ETAs for both full trains and single wagons ; a unique capability within the market. The improved visibility across all types of rail transport will be available globally for Shippeo customers. In addition, Everysens covers the full transport process , including tendering, collaborative smart planning, freight letters and CO2 emissions.
By integrating their respective shipment ETAs, both companies are able to offer their customers improved end-to-end visibility in a single offering, creating new opportunities for supply chain convergence and benefitting shippers with a higher level of supply chain transparency and optimised logistics flows.
“As shippers face more and more supply chain challenges around the world as a result of disruptive global events, they want to know when their shipments will reach their final destination,” explains Lucien Besse, COO and Co-founder at Shippeo. “With sustainability playing an increasingly important role in transportation management, rail is becoming a popular means of intermodal transport. However, visibility over rail shipments has not been easy for shippers to achieve. The partnership between Shippeo and Everysens increases shippers’ trust in rail and multimodal deliveries , providing them with critical monitoring milestones, as well as the ability to measure and improve their processes.”
“Rail is already an important part of multimodal logistics. Effects of the EU Green Deal are quickly positioning rail further as the future of freight,” says Dr. Youness Lemrabet, CEO and Founder of Everysens. “The target is clear: 30% modal share for rail by 2030, with an estimated impact of 290 million tons of CO2 saved . To reach this, rail needs newcomers, for whom intermodal is the primary entry point. With this partnership, we can connect the dots between rail and first- and last-mile transport modes, to make modal shift truly happen .”
About Shippeo
Shippeo
is a global leader in real-time multimodal transportation visibility, helping major shippers and logistics service providers operate more collaborative, automated, sustainable, profitable, and customer-centric supply chains with highly accurate, real-time operational visibility and perfect workflow orchestration. Their Multimodal Visibility Network integrates with more than 875 TMS, telematics and ELD systems, enabling Shippeo’s platform to provide instant access to real-time shipment tracking across all transport modes, in a single portal, through an intuitive user experience. A proprietary and industry-leading machine learning algorithm offers unmatched ETA accuracy, allowing supply chain companies to quickly anticipate problems, proactively alert customers, efficiently manage exceptions with collaborative workflows, and accurately measure CO2 and GHG emissions from supply chain transport. Hundreds of customers, including global brands like Coca-Cola HBC, Carrefour, Renault Group, Schneider Electric, Total, Faurecia, Saint-Gobain and Eckes Granini, trust Shippeo to track more than 28 million shipments per year across 75 countries. Learn more at www.shippeo.com
LinkedIn
, Facebook
, Twitter
About Everysens
Decarbonising transport, one train at a time. Everysens offers the first Transport Visibility & Management System (TVMS): a TMS specialised in the predictive planning of your rail and intermodal transport by integrating real-time visibility into your processes. This collaborative tool simplifies exchanges between the logistics operator, shippers, carriers and customers for a better execution of transport flows. Integrated with more than 40 rail operators and wagon rental companies, Everysens brings the whole rail and intermodal ecosystem to their industrial customers. Everysens is trusted by the largest chemical, cereals, steel and construction materials companies (among which Arkema, TotalEnergies, ArcelorMittal, HeidelbergCement, CRH) to empower their CO2 and modal shift strategies thanks to simpler rail processes.
Learn more at www.everysens.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220609005844/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
